GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.
about
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responsesEmerging Link between Alzheimer's Disease and Homeostatic Synaptic PlasticityDysfunction of NMDA receptors in Alzheimer's diseaseMT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease.Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors.Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations.Chronic traumatic encephalopathy: a critical appraisal.Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis.Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks.NMDA-receptor activation but not ion flux is required for amyloid-beta induced synaptic depression.Amyloid-β as a modulator of synaptic plasticityLongitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents.mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivoCellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death.Synaptic activity and Alzheimer's disease: a critical update.From Molecular Circuit Dysfunction to Disease: Case Studies in Epilepsy, Traumatic Brain Injury, and Alzheimer's Disease.Soluble Aβ oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance.Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression.Expression of Phenotypic Astrocyte Marker Is Increased in a Transgenic Mouse Model of Alzheimer's Disease versus Age-Matched Controls: A Presymptomatic Stage Study.Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.Local and Use-Dependent Effects of β-Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis.NMDA receptor as a newly identified member of the metabotropic glutamate receptor family: clinical implications for neurodegenerative diseases.Impaired glutamate recycling and GluN2B-mediated neuronal calcium overload in mice lacking TGF-β1 in the CNS.Perispinal etanercept: a new therapeutic paradigm in neurology.New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc.New developments on the role of NMDA receptors in Alzheimer's diseaseAlzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connectionsBiochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β.CaMKII: claiming center stage in postsynaptic function and organization.Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral.The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease.Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.NMDA receptors and BAX are essential for Aβ impairment of LTP.Association between NMDA receptor subunit 2b gene polymorphism and Alzheimer's disease in Chinese Han population in Shanghai.Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation.Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.Release of Full-Length PrP(C) from Cultured Neurons Following Neurotoxic ChallengesEffects of Low Amyloid-β (Aβ) Concentration on Aβ1-42 Oligomers Binding and GluN2B Membrane Expression.
P2860
Q21560808-AA96D4CE-71EB-45C4-972B-F4397EE848ABQ26750576-E5682EA8-F65A-4D10-B1F6-B181638FEFF0Q26766185-7F37A3F9-C447-4030-A22A-A40D58BABD37Q27327525-3CB0D499-1720-4F21-A7F3-C840C6E005DAQ27343149-CC7C0AAE-0E2B-4F5D-8BE7-33C086A9A651Q30453949-10498442-3320-4699-8BD6-71FCE8220B79Q30688850-96330285-94BD-4F51-AD27-EEA686BC25B4Q34213029-5C06A2E4-FF84-4007-85ED-2DA51A40C503Q34516825-6FF0E6B0-0C8D-49BC-BD00-0A62629F9143Q34524924-805C3C08-C1B2-4210-8A2B-3412FF876C14Q34764283-B54BB456-D260-4AFA-84AA-4DA9A2329A63Q34814145-BB6B9EAF-C908-4636-A9BD-1FBCBD8E23D6Q34950867-746B336F-B540-4921-9669-F04ACD8618E3Q35160799-6C475F8D-7BE7-4821-8D66-8BFA16A8B69AQ35750233-3F98C8DB-3155-42C2-95B5-BFC1D1EDA1D1Q36245276-91C4A102-57DF-4E5A-948B-44C6AE8C2CC3Q36271608-86B7B8FD-3E14-4B27-A89E-11C2267C9797Q36652001-A7DB206A-5D41-4474-AC77-D9FFC44FFA23Q36673182-7082E42E-A495-4E48-A93E-31D1A5D28154Q37273728-B184396D-B24E-47FA-B699-4839A7680308Q37350693-7E5713BF-DB67-4BA6-837F-2976317465EDQ37444982-F002BCD8-D82F-451C-B916-E0F054F239CFQ37462558-9A8D3257-2BEF-4A77-9DD0-2BAF9B19DE2EQ37693974-3EEE0DFA-8B71-48E8-B96F-4DC493EEDB88Q37762260-A8DC525D-31F9-488B-ADF2-5BAB80C1D87AQ37893463-7D12004C-7691-44E1-B194-ED0FC6EDE770Q37941166-8C2A57E9-48FC-49EB-893D-E42FEDE07BBAQ38014513-D5800784-78AC-48EC-9A44-CC963979D8D1Q38016898-DB2DDB65-DC3E-4E77-B4EC-6A308680BAEDQ38153617-A96E286C-3995-414C-A406-520F6E399216Q38181739-59D0EE24-1411-4E46-80CD-2B010D79379CQ38185273-650189C0-9F11-4B23-941A-A926B173009BQ38592265-1366B017-2FBD-4101-B56E-4F2ED1F5EFF2Q38831521-973E7745-0FA7-4EEA-8102-F899FBB26076Q40408420-20E24BAA-76DB-43D6-B37C-34B5ADFD0947Q41442372-0E66738D-52E3-4598-95A3-9FE4B8A29266Q42273974-979B8FB3-2203-40AC-B666-50429140AA64Q42293352-66C9A975-2D86-44FC-9726-83A7957F6257Q42410869-DDBFEAC0-27A5-4D44-B7FB-040F0077C261Q42531948-CE29EFAB-2451-4C0B-8D57-6529FAF25A12
P2860
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@en
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@nl
type
label
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@en
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@nl
prefLabel
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@en
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo.
@nl
P2860
P356
P1476
GluN2B subunit-containing NMDA ...... plasticity disruption in vivo
@en
P2093
Igor Klyubin
Roger Anwyl
P2860
P304
20504-20509
P356
10.1073/PNAS.0908083106
P407
P577
2009-11-16T00:00:00Z